William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating on January 14.Stay Ahead of the ...

By Sneha S K and Christy Santhosh (Reuters) -AbbVie plans to "commit less capital" towards experimental medicines for ...

AbbVie will commit "less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the ...

About Leap Therapeutics Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized ...

AbbVie stock has been beaten down recently because an $8.7 billion investment the company made in Cerevel Therapeutics in 2023 hasn't worked out as planned. This November, we learned that ...

On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for ...

Icalcaprant is under clinical development by Cerevel Therapeutics and currently in Phase I for Bipolar I Disorder. According to GlobalData, Phase I drugs for Bipolar I Disorder have a 100% phase ...

Pharma group AbbVie raised $15bn from an investment-grade bond sale in February to help fund its acquisitions of ImmunoGen and Cerevel Therapeutics, while other large issuers in 2024 included ...